The Tokyo-based company was established in 2017 and is developing clinical tests in the field of reproductive medicine and gynecology. Currently, they are focused on the analysis of the microflora in the uterus which should be controlled during in-vitro fertilization. The technology is based on next-generation sequencing.
Source: Varinos news release, January 29, 2018
Request a quote for deeper information from